Background Biomarkers have revolutionized the management of colorectal cancer (CRC),
facilitating early detection, prevention, personalized treatment, and minimal residual disease …

Technological advancements in cell-free DNA (cfDNA) liquid biopsy have triggered
exponential growth in numerous clinical applications. While cfDNA-based liquid biopsy has …

Background Blood-based biomarker tests can potentially change the landscape of colorectal
cancer (CRC) screening. We characterize the conditions under which blood test screening …

There are several timely, important, and novel aspects to colorectal cancer (CRC) screening
that are highlighted in the study by Aziz et al. 1 Despite good evidence to illustrate the …

Background: Colorectal cancer (CRC) is a leading cause of death worldwide. Despite its
preventability through screening, compliance still needs to improve due to the invasiveness …

Conventional screening options for colorectal cancer (CRC) detection are mainly direct
visualization and invasive methods including colonoscopy and flexible sigmoidoscopy …

Cancer has become the second leading cause of death in the world, and more than 50% of
cancer patients are diagnosed at an advanced stage. Early diagnosis of tumours is the key …

Liquid biopsies offer a less invasive alternative to tissue biopsies for diagnosis, prognosis,
and determining therapeutic potential in renal cell carcinoma (RCC). Unfortunately, clinical …

Colonoscopy remains the most commonly used colorectal cancer screening test in the
United States. A substantial portion of the screening population value the high sensitivity of …

Colorectal cancer (CRC) ranks third globally in cancer incidence, with 1.4 million new cases
annually in 2012, causing 694 000 deaths [1]. In 2020, there were around 1.93 million new …